Výsledky vyhledávání

Comparative efficacy and safety of rimegepant, ubrogepant, and lasmiditan for acute treatment of migraine: a network meta-analysis

Autor: Alexandra Thiry, Gilbert L'Italien, Vladimir Coric, Robert Croop, James Moren, Linda Harris, Alison Deighton, Karissa Johnston, Evan Popoff, Parisa Dabirvaziri

Publikováno v: Expert Review of Pharmacoeconomics & Outcomes Research. 22:155-166

Objective In the absence of head-to-head comparisons, the objective of this study was to conduct a network meta-analysis (NMA) to indirectly compare the relative efficacy and safety of rimegepant, ubrogepant, and lasmiditan for the acute treatment of

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d0f8011e0b07aa41b80eb4b5a1253a0b
https://doi.org/10.1080/14737167.2021.1945444

Zobrazit plný text záznamu

Matching‐adjusted indirect comparisons of oral rimegepant versus placebo, erenumab, and galcanezumab examining monthly migraine days and health‐related quality of life in the treatment of migraine

Autor: Alexandra Thiry, Lauren Powell, James Moren, Vladimir Coric, Robert Croop, Evan Popoff, Gilbert L'Italien, Linda Harris, Karissa Johnston

Publikováno v: Headache

Objective Rimegepant is an orally administered small‐molecule calcitonin gene‐related peptide (CGRP) receptor antagonist, with demonstrated efficacy in the acute treatment of migraine. Recent estimates from a single‐arm trial (BHV3000‐201) ha

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::60ede709cc1b1ac6829f4940e2f73c1a
https://doi.org/10.1111/head.14128

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání